Compare · CBLI vs INCY
CBLI vs INCY
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $22.96B, about 432.4x CBLI ($53.1M).
- INCY has hit the wire 7 times in the past 4 weeks while CBLI has been quiet.
- INCY has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- Incyte Corp.
- Price
- -
- -
- Market cap
- $53.1M
- $22.96B
- 1M return
- -
- -11.36%
- 1Y return
- -
- +31.32%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest INCY
- Incyte to Report Third Quarter Financial Results
- Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
- SEC Form 4 filed by Incyte Corp.
- Director Baker Bros. Advisors Lp was granted 644 shares (SEC Form 4)
- Director Clancy Paul J was granted 203 shares, increasing direct ownership by 0.79% to 25,838 units (SEC Form 4)
- Director Harrigan Edmund was granted 206 shares, increasing direct ownership by 0.89% to 23,225 units (SEC Form 4)
- MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
- EVP, Chief Strategy Officer Gardner David H covered exercise/tax liability with 920 shares, decreasing direct ownership by 5% to 15,904 units (SEC Form 4) to satisfy withholding tax
- Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio